Results 121 to 130 of about 4,629,468 (340)

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Interleukin‐13 immune gene therapy prevents CNS inflammation and demyelination via alternative activation of microglia and macrophages

Glia, 2016
Detrimental inflammatory responses in the central nervous system are a hallmark of various brain injuries and diseases. With this study we provide evidence that lentiviral vector‐mediated expression of the immune‐modulating cytokine interleukin 13 (IL‐13)
C. Guglielmetti, D. Le Blon, E. Santermans, Angélica Salas-Pérdomo, J. Daans, Nathalie de Vocht, Disha Shah, C. Hoornaert, Jelle Praet, J. Peerlings, F. Kara, Christian Bigot, Z. Mai, H. Goossens, N. Hens, S. Hendrix, M. Verhoye, A. Planas, Z. Berneman, A. Van der Linden, P. Ponsaerts   +20 more
semanticscholar   +1 more source

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Avaliação das citocinas IL-10 e IL-13 como mediadores na progressão da fibrose de Symmers em portadores de esquistossomose mansônica na forma hepatoesplênica

Revista do Colégio Brasileiro de Cirurgiões
OBJETIVO: Investigar os níveis de IL-10 e IL-13 no soro de portadores da esquistossomose mansônica na forma hepatoesplênica (EHE), avaliando o papel destas citocinas no desenvolvimento da fibrose hepática.
Carlos Teixeira Brandt, Mario Rino, Maira Galdino da Rocha Pitta, Janinne Siqueira Muniz, Diego de Oliveira Silveira, Célia Maria Machado Barbosa de Castro   +5 more
doaj   +1 more source

Current review of genetically modified lactic acid bacteria for the prevention and treatment of colitis using murine models [PDF]

, 2015
Inflammatory Bowel Diseases (IBD) are disorders of the gastrointestinal tract characterized by recurrent inflammation that requires lifelong treatments.
Azevedo, Vasco, Bermudez Humaran, Luis G., Chatel, Jean Marc, de Moreno, Maria Alejandra, del Carmen, Silvina Andrea, Langella, Philippe, Leblanc, Jean Guy Joseph, Miyoshi, Anderson   +7 more
core   +1 more source

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity. [PDF]

, 2017
Interleukin-15 (IL-15) is a potent cytokine that increases CD8+ T and NK cell numbers and function in experimental models. However, obstacles remain in using IL-15 therapeutically, specifically its low potency and short in vivo half-life.
Alpdogan, Onder, Bailey, Cavan P, Budak-Alpdogan, Tulin, Buyukgoz, Cihangir, Flomenberg, MD, Neal, Jeng, Emily K, Panis, Michelle M, Sauter, Christopher T, Wong, Hing C   +8 more
core   +3 more sources

Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of
Pannathat Soontrapa, Iago Pinal‐Fernandez, Pritikanta Paul, Michael P. Skolka, Margherita Milone, Min Shi, Mithun V. Shah, Maria Casal‐Dominguez, Katherine Pak, Andrew L. Mammen, Teerin Liewluck   +10 more
wiley   +1 more source

Progress in the application of dupilumab for non-atopic dermatitis

Pifu-xingbing zhenliaoxue zazhi
Dupilumab inhibits Th2-mediated inflammatory responses by specifically blocking the signaling pathways of interleukin-4 and interleukin-13. Recently, in addition to its approved indication for the treatment of moderate-to-severe atopic dermatitis ...
SHI Xiwu, LIU Qing, WANG Xiuli, HAN Yang, HU Zhulin   +4 more
doaj   +1 more source

Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study [PDF]

, 2012
Background: Interleukin-22 (IL-22), recently identified as a crucial parameter of pathology in experimental liver damage, may determine survival in clinical end-stage liver disease.
Bachmann, Malte, Brunner, Friederike, Filmann, Natalie, Herrmann, Eva, Kapper, Lisa, Kronenberger, Bernd, Mühl, Heiko, Pfeilschifter, Josef Martin (Prof. Dr.), Piiper, Albrecht, Rudloff, Ina, Waidmann, Oliver, Zeuzem, Stefan   +11 more
core   +1 more source